4D Pharma PLC ADR (LBPS)

Name: 4D Pharma PLC ADR (LBPS) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: 4D Pharma PLC ADR (LBPS)

Stock Card

$1.65

$0.00 (0.00%)

As on 28-Jul-2022 09:30EDT

Market cap

$37 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

1.3

Div. Yield

0 %

4D Pharma PLC ADR (LBPS) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 1.65 High: 1.65

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$-32 Mln
ROE

-0.9 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-0.5
Debt to Equity

0.4
Book Value

$--
EPS

$--
Face value

--
Shares outstanding

22,542,200

8 Years Aggregate

CFO

£-148.69 Mln

EBITDA

£-157.31 Mln

Net Profit

£-145.53 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
4D Pharma PLC ADR (LBPS)	-69.7	0.0	-56.1	-81.9	--	--	--
BSE Sensex^*	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8

As on 28-Jul-2022 | *As on 28-Aug-2026

The underlying data is unavailable.

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
4D Pharma PLC ADR (LBPS)	1.7	37.2	0.7	-31.9	--	-105.8	--	1.3
OKYO Pharma Ltd ADR (OKYO)	1.7	80.8	0.0	-9.0	--	-263.8	--	6.4
Silence Therapeutics PLC (SLN)	13.4	824.8	0.6	-59.9	-9,892.6	-118.9	--	21.3

Shareholding Pattern

View Details

About 4D Pharma PLC ADR (LBPS)

4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004... for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom. Read more

CEO & Exec. Director

Mr. Duncan Joseph Peyton
CEO & Exec. Director

Mr. Duncan Joseph Peyton
Headquarters

Leeds
Website

https://www.4dpharmaplc.com

FAQs for 4D Pharma PLC ADR (LBPS)

What is the current share price of 4D Pharma PLC ADR (LBPS) Today?

The share price of 4D Pharma PLC ADR (LBPS) is $1.65 (NASDAQ) as of 28-Jul-2022 09:30 EDT. 4D Pharma PLC ADR (LBPS) has given a return of -81.89% in the last 1 years.

What is the current PB & PE ratio of 4D Pharma PLC ADR (LBPS)?

Since, TTM earnings of 4D Pharma PLC ADR (LBPS) is negative, P/E ratio is not available.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2021	--	--
2020	--	--
2019	--	--
2018	--	--
2017	--	--

What is the 52 Week High and Low of 4D Pharma PLC ADR (LBPS)?

The 52-week high and low of 4D Pharma PLC ADR (LBPS) are Rs -- and Rs -- as of 29-Aug-2026.

What is the market cap of 4D Pharma PLC ADR (LBPS)?

4D Pharma PLC ADR (LBPS) has a market capitalisation of $ 37 Mln as on 28-Jul-2022. As per SEBI classification, it is a company.

Should I invest in 4D Pharma PLC ADR (LBPS)?

Before investing in 4D Pharma PLC ADR (LBPS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.